Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: COVID-19 NVX-CoV2373 Vaccine (Novavax) TM
Active ingredients: covid-19 (nvx-cov2373) vaccine
What it is used for
NUVAXOVID has approval for the indication: Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations.
How to take it
The way to take this medicine is: Intramuscular. This medicine is given through a needle inserted into the muscle beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from Light
- Shelf lifetime is 9 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
a colourless to slightly yellow, clear to mildly opalescent suspension
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient covid-19 (nvx-cov2373) vaccine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Need more information?
These trusted information partners have more on this topic.
